Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention

Heart

Volumn 93, Issue 6, 2007, Pages 703-707

  Bonello, Laurent ^a   Sbragia, Pascal ^a   Amabile, Nicolas ^a   Com, Olivier ^a   Pierre, Sandrine V ^b   Levy, Samuel ^a   Paganelli, Franck ^a  

^a HÔPITAL NORD   (France)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; TRIMETAZIDINE; TROPONIN I;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART PROTECTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; FEMALE; HEART INJURIES; HUMANS; MALE; MIDDLE AGED; PREMEDICATION; PROSPECTIVE STUDIES; STENTS; TRIMETAZIDINE; TROPONIN I; VASODILATOR AGENTS;

EID: 34249283806     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.107524     Document Type: Article

References (21)

1. Selvanayagam JB, Porto I, Chanon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury. Circulation 2005;111:1027-32.
2. Herrmann J, Von Birgelen C, Haude M, et al. Prognostic implication of cardiac troponin T increase following stent implantation. Heart 2002;87:549-53.
3. Lopaschuk GD. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol 1998;82:14K- 17K.
4. McClellan KJ, Plosker GL. Trimetazidine: a review of its use in stable angina pectoris and others conditions. Drugs 1999;58:143- 57.
5. Steg PG, Grollier G, Gallay P, et al. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 2001;77:263-73.
6. Padadopoulos CL, Kanonidis IE, Kotridis PS, et al. The effect of trimetazidine on reperfusion arrhythmia in acute myocardial infarction. Int J Cardiol 1996;55:137-42.
7. The EMIP-FR Group (European Myocardial Infarction Project-Free Radicals). Effect on 48-h intravenous trimetazidine on short and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; a double-blind, placebo-controlled, randomized trial. Eur Heart J 2000;21:1537-46.
8. Di Pasquole P, Lo verso P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long term results. Cardiovasc Drug Ther 1999;13:423-8.
9. Kober G, Buck T, Sievert H, et al. Myocardial protection during percutaneous transluminal angioplasty: effects of trimetazidine. Eur Heart J 1992;13:1109-15.
10. Kovar U, Monrad ES, Sherman W, et al. A randomized trial of stenting with or without balloon predilatation for the treatment of coronary artery disease. Am Heart J 2001;142:e9.
11. Smith SC Jr, Dove JT, Jacobs AK, et al. Guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001;37:2215-39.
12. Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study. Arch Mal Cœur Vaiss 1986;79:1331-6.
13. Scholler B, Hennen B, Pohl A, et al. Acute and subacute stent occlusion; risk reduction by ionic contrast media. Eur Heart J 2001;22:385-91.
14. Genissel P, Chodjania Y, Demolis JL, et al. Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. Eur J Drug Metab Pharmacokinet 2004;29:61-8.
15. Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol 2003;17:133-45.
16. Pomin M, Harpey C, Allai J, et al. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study. Clin Trials Metaanal 1994;29:49-56.
17. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid-oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme thiolase. Circ Res 2000;86:580-8.
18. Lopaschuk GD, Rick B, Panakkezhum T, et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003;93:e33-7.
19. Morin D, Elimadi A, Sapena R, et al. Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br J Pharmacol 1998;123:1385-94.
20. Weiss JN, Korge P, Honda HM, et al. Role of the mitochondrial permeability transition in myocardial disease. Circ Res 2003;93:292-301.
21. Argaud L, Gomez L, Gateau-Roesch O, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005;39:893-9.